Search results
Results from the WOW.Com Content Network
Inspire Medical’s outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA has labeled a recall of Inspire Medical Systems, Inc.’s (NYSE:INSP) nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire initiated a recall of ...
For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact Ezgi Yagci Vice President, Investor Relations ezgiyagci@inspiresleep.com 617-549-2443 11/15/2024 08:00 -0500
In April 2018, an Inspire data scientist was an author of a Nature Genetics correspondence [16] about ways to close the"terminology gap" between medical professionals and patients. Also in 2018, Inspire collaborated with ProPublica and Memorial Sloan Kettering Cancer Center in research that led to a paper in the Journal of Oncology Practice. [17]
The accuracy of medical journalism varies widely. Reviews of mass media publications have graded most stories unsatisfactory, although there were examples of excellence. [2] [3] Other reviews have found that most errors in mass media publications were the result of repeating errors in the original journal articles or their press releases. [4]
Medical Information Technology, Inc., shortened to Meditech, is a privately held Massachusetts-based software and service company that develops and sells information systems for healthcare organizations.
Inspire (INSP) delivered earnings and revenue surprises of 7.69% and 9.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?